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Cathepsin K is a cysteine proteinase which is believed to contribute to osteoarthritis (OA) pathogenesis.
This brief report evaluates the effect of the novel selective cathepsin K inhibitor AZ12606133 on cartilage
metabolism in the DunkineHartley guinea pig model of spontaneous OA. In parallel, electrophysiological
studies were performed to determine whether acute and chronic treatment with the cathepsin K
inhibitor could alter joint nociception. Acute treatment of OA knees with AZ12606133 had no effect on
joint afferent nerve activity; however, prolonged (1 month) administration of the cathepsin K inhibitor
delivered via a chronically implanted osmotic pump signiﬁcantly reduced mechanosensitivity in
response to both non-noxious and noxious joint movements. Urinal concentrations of the cartilage
breakdown products cross-linked C-telopeptides of type II collagen (CTXII) were also reduced by chronic
cathepsin K inhibition. These data suggest that prolonged AZ12606133 administration can reduce
cartilage turnover and joint nociception in the DunkineHartley guinea pig model of spontaneous OA.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Experiments were carried out on male 9-month-old Dun-
kineHartley guinea pigs (0.78e1.17 kg). Animals of this age typi-
cally show moderate signs of osteoarthritis (OA) and joint pain1,2.
Animals were housed in individual cages at room temperature with
a 12 h light: 12 dark cycle and free access to food and water. All
animal handling and surgical procedures carried out received prior
approval by the University of Calgary Animal Care Committee.
Electrophysiological recording of knee joint afferents
A more detailed overview of the joint afferent recording tech-
nique has been previously reported3. Brieﬂy, animals were deeply
anaesthetised by ethyl carbamate (25% Urethane, 2 g/kg i.p.) and
a medial incision was made in the right hindlimb of the guinea pig.
The saphenous nerve was then isolated in the inguinal region and
cut centrally to avoid spinal reﬂexes. Thin fascicles were dissected
from the main trunk of the nerve and placed over a platinum
recording electrode. The receptive ﬁeld of the recorded nerve ﬁbre
was determined by gently palpating the surface of the hindlimb
with a thin glass rod. Only afferents with a discrete receptive ﬁeld
within the joint were used for experimental assessment. Single unitJason J. McDougall, Depart-
ary, 3330 Hospital Drive NW,
x:1-403-2103949.
gall).
s Research Society International. Paction potentials were ampliﬁed and all the signals underwent
analogue-to-digital conversion by a data acquisition system
(CED1401, Cambridge Electronic Design, Cambridge, UK).
The muscle relaxant gallamine triethiodide (50 mg/kg i.v.) was
injected to eliminate neural interference arising from hindlimb
muscle afferents. The right femur was clamped in a stereotaxic
frame and the right hindpaw secured in a rigid Perspex boot
thereby immobilising the hip and ankle respectively. Rotational
movements could then be applied to the knee joint and resultant
torque levels were standardised and measured by a force
transducer and torque meter (MVD2510; Hottinger-Baldwin Mes-
stechnik, Darmstadt, Germany). In the acute pain studies, the
ipsilateral saphenous artery was cannulated at a point distal to the
medial articular artery to allow local close intra-arterial injection of
test agents. Joint afferent recordings were carried out for 1 min
prior to knee movement to determine the level of spontaneous
nerve activity (if any). The knee joint was then hyper-rotated and
held in this position for 10 s. This noxious movement was then
repeated at 1, 3, 5, 7, 9, 12 and 15 min following close intra-arterial
administration of either vehicle or AZ12606133 (10 mg or 100 mg in
100 ml bolus). The number of action potentials evoked during each
movement was ascertained.
In chronic pain experiments, AZ12606133 was administered
continuously for 28 days to OA guinea pigs via an implanted mini
osmotic pump (Alzet Osmotic Pumps, Cupertino, CA, USA). Animals
were deeply anaesthetised (2e5% isoﬂurane in 100% O2; 1 L/min)ublished by Elsevier Ltd. All rights reserved.
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2.5 ml/h; total volume¼ 2 ml) containing either vehicle or
AZ12606133-007 (0.5 mg/kg/day) was placed subcutaneously in the
dorsum of the guinea pig. Animals were allowed to recover before
being prepared for electrophysiological recording. In these exper-
iments, afferent nerve activity was recorded in response to both
normal joint rotation (40 mNm) and hyper-rotation (65 mNm).
Each movement lasted 10 s and was repeated three times. The
mean ﬁring rate of the nerve ﬁbre over the three movements was
calculated as before.
Chronic administration of AZ12606133 and cartilage
degradation
On the ﬁnal day of chronic administration of AZ12606133, (Day
28), urine was collected over a 6 h period by placing guinea pigs in
metabolism cages. The urine was stored at 20C until later
analysed for evidence of cartilage turnover using the cross-linked
C-telopeptides of type II (CTXII) collagen assay, (Cartilaps ELISA,
Nordic Bioscience, Herlev, Denmark). Samples were normalised to
creatinine levels to correct for urine volume differences.
Pharmacokinetic analyses were carried out on day 26 of
AZ12606133-dosed animals. Blood samples were taken via cardiac
heart puncture from terminally anaesthetised animals and
aliquotted into lithiumeheparin coated tubes. Samples were
centrifuged at 12,000g for 3 min and the supernatant (serum) was
frozen at e20C until analysed for drug concentration.
Statistics
All data were normally distributed and expressed as means and
95% conﬁdence intervals for “n” observations. The effect of acute
administered drugs between animal groups was analysed by either
one- or two-way analysis of variance (ANOVA). Urinary CTXII levels
and effect of chronic administered drugs were analysed using
a Student’s t test, (two-tailed). P< 0.05 was considered statistically
signiﬁcant.
Effect of AZ12606133 on joint nociception
Acute local administration of AZ12606133 (10 mg or 100 mg close
intra-arterial) had no observable effect on joint afferent sponta-
neous activity nor on movement-evoked ﬁring rate (Fig. 1). A two-
factor ANOVA conﬁrmed that there was no signiﬁcant difference
between animals given vehicle and those receiving the cathepsin K
inhibitor (P¼ 0.29; n¼ 6e11).
Knee joint afferents in old guinea pigs often ﬁre even at rest. This
spontaneous activity in animals having received a slow infusion of
vehicle for a month was found to be 52.9 (lower limit: 24.27, upperFig. 1. Effect of acutely administered AZ12606133 on knee joint afferent ﬁring rate in
response to hyper-rotation of the knee. Blockade of cathepsin K had no effect on OA
joint mechanosensitivity during this time period. Data are means and 95% conﬁdence
intervals. n¼ 6e11 ﬁbres.limit: 81.53) action potentials/min (n¼ 26 ﬁbres). In contrast, the
cohort of age-matched guinea pigs treated with AZ12606133
exhibited aﬁring rate of only 8.8 (lower limit: 0.33, upper limit: 17.21)
action potentials/min (n¼ 18 ﬁbres). This reduction in spontaneous
activity between the two groups was statistically signiﬁcant
(P¼ 0.035, unpaired Student’s t test). Moreover, chronic administra-
tion of AZ12606133 caused both non-noxious and noxious move-
ment-evokedafferentﬁringrate to fall byapproximately50%(Table I).Effect of AZ12606133 on cartilage metabolism
Chronic dosing of guinea pigs with AZ12606133 at 0.5 mg/kg/day
gave a mean blood concentration of 8.8 (lower limit: 6.128, upper
limit: 11.47) ng/ml. Vehicle treated animals had urine CTXII levels of
1.123 (lower limit: 0.658, upper limit: 1.588) ng/ml (per mmol/L
creatinine) (n¼ 8). In contrast, CTXII levels from AZ12606133-
treated animals were lower by approximately 63% to 0.405 (lower
limit: 0.218, upper limit: 0.598) ng/ml (per mmol/L creatinine,
P¼ 0.0045, unpaired Student’s t test; n¼ 8).
This brief report aimed to elucidate the effect of a novel selective
cathepsin K inhibitor (AZ12606133) on cartilage integrity and joint
nociception using the DunkineHartley guinea pig model of spon-
taneous OA. Cathepsin K is a cysteine proteinase which is believed
to contribute to OA pathogenesis since it is upregulated in OA joints
near areas of cartilage destruction and bone resorption4,5. Here we
used CTXII in the urine as a biomarker of cartilage metabolism
since this molecule is a product of type II collagen turnover. In the
9-month-old guinea pig, the growth plate of many joints is not yet
ossiﬁed so urinary CTXII may reﬂect turnover of mineralized
articular cartilage6 as well as growth plate cartilage in this model
system. Chronic treatment of DunkineHartley guinea pigs for 1
month with AZ12606133 caused a 63% reduction in CTXII excretion
thereby demonstrating the inhibition of cartilage (growth plate
and/or mineralized articular cartilage) turnover with cathepsin K
inhibition. One of the major limitations of this study was that
effects of cathepsin K inhibition on cartilage were not able to be
evaluated by histopathology or structural imaging. An improve-
ment in joint morphology by AZ12606133 requires validation in
a larger more in depth study. Another limitation relates to the lack
of measurement of CTXII in the synovial ﬂuid. This could have
provided stronger evidence for a direct effect of the cathepsin K
inhibitor on articular cartilage that could have been particularly
helpful in the absence of histology or imaging.
The effect of AZ12606133 on joint pain was also assessed in the
guinea pig OA model by electrophysiologically recording from knee
joint mechanonociceptive nerves. Acute, local administration of
AZ12606133 had no observable effect on joint afferent spontaneous
activity nor on movement-evoked afferent ﬁring rate. This absence
of neuromodulation suggests that AZ12606133 has no direct effect
on joint nociceptors which is not unexpected as there is no
evidence directly linking cathepsin K with neural function. In
contrast, chronic administration of AZ12606133 over a 1 month
period signiﬁcantly reduced joint afferent ﬁring frequency inTable I
Response of joint mechanosensory nerves to non-noxious and noxious rotation
following chronic administration of either vehicle or AZ12606133. The cathepsin K
inhibitor signiﬁcantly reduced afferent ﬁring rate with both types of movement.
Data are means and 95% conﬁdence intervals (lower limit, upper limit). Differences
in ﬁring rate were analysed using an unpaired Student’s t test
Firing rate/movement N P-value
Non-noxious Vehicle 30.85 (20.25, 41.45) 24
AZ12606133 15.68 (7.46, 23.90) 16 (0.037)
Noxious Vehicle 67.01 (42.71, 91.31) 24
AZ12606133 34.44 (22.15, 46.73) 16 (0.038)
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observation suggests that AZ12606133-induced anti-nociception is
likely related to the potential impact of cathepsin K inhibition on
disease activity. An improvement in joint integrity would lead to
enhanced joint stability and consequently a reduction in stimula-
tion of joint mechanosensitive nerves7. Furthermore, since one of
the primary origins of OA pain is thought to be activation of
exposed subchondral nociceptors either directly or via cartilage
degradation products7,8, a recovery in articular cartilage integrity
could reduce neural activation within this region. An alternative
explanation for the reduction in joint nociception following chronic
AZ12606133 administration could be that long term cathepsin K
inhibition leads to a gradual change in nerve function culminating
in a loss in joint mechanosensitivity. In a time-resolved ﬂuores-
cence resonance energy transfer assay, AZ12606133 was found to
be a potent inhibitor of human (0.99 nM) and guinea pig (0.88 nM)
full length recombinant cathepsin K. AZ12606133 also has at least
1000 fold selectivity over human cathepsin L, S and B (the family
members that display highest homology to cathepsin K), when
tested in similar assays. Whilst off target pharmacology cannot be
completely excluded, the potency and selectivity of AZ12606133
suggest that the effects on joint nociception observed during
chronic administration are attributable to selective inhibition of
cathepsin K and not other cathepsins.
The physiological relationship between structural changes in the
OA joint and the onset and duration of pain is complex and poorly
understood, but the concept that modifying or protecting the joint
from deteriorationwill subsequently reduce or prevent the onset of
pain is worthy of investigation in pre-clinical models. One of the
drawbacks to this type of work is the availability of appropriate,
validated animal models in which this relationship is robust and
amenable to testing of novel agents. Rodent models such as intra-
articular monoiodoacetate or joint injury have been shown to be
usefulmodels for testing analgesics9e11, but are considered less than
ideal for replicating the structural pathology of human OA.
Conversely, the DunkineHartley guinea pig model of naturally-
occurring OA is more attractive from the standpoint of clinical
relevance since there is no artiﬁcial derangementof the joint and the
pathology is similar to human disease1. Crucially, however, there is
a poor correlation between disease severity and nociception in this
model2 and guinea pigs are less amenable to standard pain behav-
ioural tests, such as alteredweight bearing, as both knees are equally
diseased. In the absence of suitable surrogatemeasures of joint pain
in the guinea pig, joint nociceptionhas been objectivelymeasured in
these animals by recording electrophysiologically from knee joint
primary afferents in response to non-noxious and noxious move-
ments of the knee2,12. In addition, whilst there are no proven drugs
which alter disease progression clinically, the utility of this animal
model in identifying disease modifying OA drugs is evident by the
ﬁndings that doxycycline, which lessens joint space narrowing in
man13, partially protects guinea pigs from cartilage loss14. These
independent ﬁndings suggest that the guinea pig model is ideal for
exploring structural modiﬁcation and joint nociception.
In summary, this preliminary study found that prolonged infu-
sion of AZ12606133 to OA guinea pigs reduced CTXII excretion and
joint mechanonociception. Based on these data, further studies are
warranted to evaluate the potential analgesic and chon-
droprotective effects of this cathepsin K inhibitor.
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